CHICAGO – Nivolumab and nivolumab plus ipilimumab are superior to ipilimumab alone in first-line metastatic melanoma, results from the phase III CheckMate 067 study suggest.
After a minimum of 9...
CHICAGO – Combining the immunotherapy antibodies nivolumab and ipilimumab induced more robust responses in untreated advanced melanoma when used together than as single agents, according to phase III...
Among patients with single-nodule hepatocellular carcinomas diagnosed by computed tomography, further imaging with gadoxetic acid–enhanced magnetic resonance (MR) revealed more tumors and was tied to...
CHICAGO – For the first time ever, a new drug has shown a survival advantage – albeit a small one – in metastatic soft tissue sarcomas, diseases that are almost without exception unresponsive to...
CHICAGO – Complete lymph node dissection did not improve survival in a prospective, randomized trial of 483 patients with stage III melanoma and micrometastases in their sentinel lymph node...
CHICAGO – Progression-free survival for patients with rituximab-refractory indolent non-Hodgkin’s lymphoma was effectively doubled with a combination of obinutuzumab and bendamustine, compared with...
CHICAGO – Immune checkpoint inhibition with nivolumab every 2 weeks provides a better response than does standard treatment for advanced liver cancer, phase I/II results suggest.
The overall...
WASHINGTON – Even wonder drugs have their limits: Aspirin use was associated with a significant reduction in the incidence of noncardiac gastric adenocarcinoma, but it had no effect on the incidence...
GENEVA – Testing for mutations in the epidermal growth factor receptor gene has revolutionized treatment of advanced non–small cell lung cancer, but a significant proportion of patients with these...
A 3-year study of over 2,000 cancer survivors revealed that information seeking among cancer survivors varied over time and was often contingent on the specific type of cancer.
With the help of the...
